Skip to main content

Table 2 Cost inputs used in the Greek model

From: Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

Model input

Costs

Data source

Ranibizumab acquisition costa

€781.52

Official price bulletin—Greek ministry of health; August 2014

Aflibercept acquisition cost

€718.83

Official price bulletin—Greek ministry of health; August 2014

Laser therapy cost (per visit)

€118

Weighted sum of the different charges as per the Greek legislature, depending on the setting of laser therapy (inpatient, outpatient)

Administration costs

€66

Weighted sum of the different charges as per the Greek legislature, depending on the setting of administration (out-patient, hospital 1 day clinic visit, hospital 1 day surgery visit, private physician visit)

Cost of blindness (annual)

€4344

Min. Dec. Π3α/Φ. 18/Γ.Π.oik.63,731; FEK 931 Β’/21-5-2008

  1. a The prices for pharmaceutical products reported in the table are the ex-factory prices that are officially published in the Price Bulletin issued by the Greek authorities. The acquisition prices incorporated in the model for the purposes of this local adaptation were the hospital prices reduced by the rebates that correspond to the third party payer, EOPYY